Page Image

Aggressive B-Cell Lymphoma

The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.

Advertisement
Advertisement
Melissa BadamoAcute Myeloid Leukemia | May 19, 2025
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Melissa BadamoPrint | May 8, 2025
Dr. Locke is a lead investigator of the ZUMA-1 and ZUMA-7 trials, which led to the FDA approval of axi-cel.
Andrew MorenoAggressive B-Cell Lymphoma | April 30, 2025
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MDAggressive B-Cell Lymphoma | April 24, 2025
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHPTransplantation & Cellular Therapy | April 15, 2025
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Nichole TuckerAggressive B-Cell Lymphoma | April 15, 2025
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
Nichole TuckerAggressive B-Cell Lymphoma | April 9, 2025
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Nichole TuckerAggressive B-Cell Lymphoma | April 1, 2025
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Andrew MorenoTransplantation & Cellular Therapy | March 26, 2025
Azercabtagene zapreleucel applies a novel approach of combining lymphodepletion chemotherapy with interleukin-2.
Melissa BadamoAcute Lymphoblastic Leukemia | March 14, 2025
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Melissa BadamoAggressive B-Cell Lymphoma | March 11, 2025
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
Andrew MorenoMyeloma | March 10, 2025
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.